Latest Safety News

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.

BCI Minerals reports robust progress in its Mardie Salt and Potash Project, achieving financial close on a $981 million debt facility and advancing construction beyond the halfway mark. The company maintains a strong focus on sustainability and safety as it targets first salt shipment in Q2 FY27.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

Babylon Pump & Power Ltd reports robust H1 FY25 results with $1.8M positive operating cash flow and $3.0M EBITDA, overcoming nickel sector challenges. The company eyes growth through new projects and acquisitions.

Aurelia Metals delivers a robust December 2024 quarter, hitting key production targets and marking a milestone with first concentrate from its Federation ore. The company maintains a strong balance sheet while advancing growth projects.

Aurelia Metals delivered a robust December quarter, marked by strong cash flow, increased metal output, and the successful processing of its first ore from the Federation mine, underpinning its FY25 guidance.

Boss Energy has officially declared commercial production at its Honeymoon Uranium Project following a strong operational ramp-up, with production and cost guidance reinforcing its position as a competitive uranium producer.

Develop Global Limited reports significant progress at its Woodlawn copper-zinc mine, with the processing plant upgrade 70% complete and underground ore production set to begin in March 2025. The company has secured a US$65 million funding facility and projects A$425 million in pre-tax cash flow over the first three years post-ramp-up.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.

MAC Copper Limited delivered a record quarterly copper production of 11,320 tonnes in Q4 2024, alongside a 12% reduction in cash costs to US$1.66/lb, setting the stage for ambitious growth targets by 2026.

29Metals delivered a solid December 2024 quarter, meeting production and cost targets while strengthening its balance sheet through a $180 million equity raising and senior debt refinancing. The company is poised to extend its Golden Grove mine life with the Gossan Valley investment.